about
Natural Products as Promising Therapeutics for Treatment of Influenza Disease.Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3.In silico analysis suggests interaction between Ebola virus and the extracellular matrixIn silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.Assessing the dispersive and electrostatic components of the selenium-aromatic interaction energy by DFT.Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in Chronic Tinnitus.In silico study of the structurally similar ORL1 receptor agonist and antagonist pairs reveal possible mechanism of receptor activation.Determination of key receptor–ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology modelArginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-TargetsVirtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel InhibitorsSynthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-TargetsMolecular modeling of 5HT2A receptor - arylpiperazine ligands interactionsIn Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantumAminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of actionIn vitro anti-influenza activity of in silico repurposed candidate drug cycrimineFunctional characterization of β2-adrenergic and insulin receptor heteromersPd(II) complexes with N-heteroaromatic hydrazone ligands: Anticancer activity, in silico and experimental target identificationNovel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy
P50
Q30379855-C1B5E8B4-A71D-488E-8D0F-7A9BAE322768Q30385922-953C0290-F8CA-4A48-ABD3-7D0FBC471CADQ35099536-D5940133-DEB3-4D0D-9A9C-9EE499C7605CQ35689217-A3198D56-973C-4C58-A70C-F1A450175A4EQ38835358-49CE6729-B69C-4D70-A47F-30FB12D4A940Q47093778-69CB3FB9-14D8-4716-ADE0-9A949890F2CFQ50675544-4D01A657-21EA-418E-8960-D16EC8E5A0A8Q60469347-797820AD-1D2F-4E58-89D2-ABA640DB83C3Q62730250-41F646FF-311E-4815-A79B-F4E65D067A6AQ63246281-BC7196CC-0D74-4C01-9489-3593DFDCC144Q64086176-ADE7D591-3263-4258-B33A-EA06A901082CQ87768253-15860E0B-5654-441A-8C02-5288AA3219AEQ88188949-FF03EE8F-D63B-4721-8E03-168FDB892199Q89607435-CCD559A9-C3B9-4E60-82BE-E3F050F531C3Q89932852-30FCAC35-14F0-4585-B4AC-72DFD7F9076BQ91305489-7F82E592-8ACE-4EF2-A70D-5463F56105F7Q91831248-0E353A70-4842-4C6B-A5F0-876946FA6C49Q92541763-3A82012C-4141-4DEF-A72B-92674612A77A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Milan Sencanski
@ast
Milan Sencanski
@en
Milan Sencanski
@es
Milan Sencanski
@nl
Milan Sencanski
@sl
type
label
Milan Sencanski
@ast
Milan Sencanski
@en
Milan Sencanski
@es
Milan Sencanski
@nl
Milan Sencanski
@sl
prefLabel
Milan Sencanski
@ast
Milan Sencanski
@en
Milan Sencanski
@es
Milan Sencanski
@nl
Milan Sencanski
@sl
P106
P21
P31
P496
0000-0002-7296-3223